MARKET

PRAX

PRAX

Praxis Precision Medicines, Inc.
NASDAQ
250.33
-2.92
-1.15%
After Hours: 249.95 -0.38 -0.15% 18:18 06/09 EDT
OPEN
258.10
PREV CLOSE
253.25
HIGH
266.60
LOW
244.16
VOLUME
465.50K
TURNOVER
--
52 WEEK HIGH
366.52
52 WEEK LOW
37.19
MARKET CAP
6.98B
P/E (TTM)
-18.7269
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Amylyx Pharmaceuticals Inc (AMLX) and Cullinan Management (CGEM)
TipRanks · 1d ago
Weekly Report: what happened at PRAX last week (0601-0605)?
Weekly Report · 1d ago
Praxis Precision Medicines (PRAX) Valuation After Vormatrigine POWER1 Miss And POWER2 Trial Pause
Simply Wall St · 3d ago
Praxis' Premium Price May Reflect Unrealistic Market Prospects In Essential Tremor
Seeking Alpha · 4d ago
Praxis Precision Medicines to present at Goldman Sachs Global Healthcare Conference
PUBT · 5d ago
Wedbush Analyst Ratings On PRAX, IDYA, EWTX, JADE
NASDAQ · 5d ago
Stock Indexes Post New Record Highs Amid AI Enthusiasm
NASDAQ · 06/02 22:09
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Heron Therapeutics (HRTX) and Praxis Precision Medicines (PRAX)
TipRanks · 06/02 20:10
More
About PRAX
Praxis Precision Medicines, Inc. is an integrated, central nervous system (CNS) precision neuroscience biopharmaceutical company, translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. The Company is applying genetic insights to the discovery and development of therapies for neurological disorders through two platforms. Its platform includes Cerebrum, a small-molecule platform, which utilizes deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies, and Solidus, an antisense oligonucleotide platform, is a targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology. The Company's product candidates include Ulixacaltamide, Vormatrigine, Relutrigine, PRAX-080, Elsunersen, and others.

Webull offers Praxis Precision Medicines Inc stock information, including NASDAQ: PRAX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRAX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PRAX stock methods without spending real money on the virtual paper trading platform.